Zak Mir talks to Arnab Basu, CEO and Claire Burgess, CFO, Kromek, as the leading developer of radiation and bio-detection technology solutions for the advanced imaging and CBRN detection segments, announced its unaudited interim results for the six months ended 31 October 2025. Revenue increased substantially to £15.0m (H1 2025: £3.7m). Adjusted EBITDA of £6.0m (H1 2025: £2.3m loss).
